ADHANSIA XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adhansia Xr, and what generic alternatives are available?
Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.
This drug has thirty-three patent family members in seventeen countries.
The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adhansia Xr
A generic version of ADHANSIA XR was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADHANSIA XR?
- What are the global sales for ADHANSIA XR?
- What is Average Wholesale Price for ADHANSIA XR?
Summary for ADHANSIA XR
| International Patents: | 33 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 2 |
| Patent Applications: | 3,544 |
| Drug Prices: | Drug price information for ADHANSIA XR |
| What excipients (inactive ingredients) are in ADHANSIA XR? | ADHANSIA XR excipients list |
| DailyMed Link: | ADHANSIA XR at DailyMed |
Recent Clinical Trials for ADHANSIA XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Purdue Pharma LP | Phase 4 |
US Patents and Regulatory Information for ADHANSIA XR
ADHANSIA XR is protected by twelve US patents and one FDA Regulatory Exclusivity.
Patents protecting ADHANSIA XR
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting ADHANSIA XR
LABELING REVISIONS RELATED TO CLINICAL STUDIES
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-006 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-004 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Purdue Pharma Lp | ADHANSIA XR | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 212038-003 | Feb 27, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADHANSIA XR
See the table below for patents covering ADHANSIA XR around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
